APA (7th ed.) Citation

Balanescu, A., Citera, G., Pascual-Ramos, V., Bhatt, D. L., Connell, C. A., Gold, D., . . . Schulze-Koops, H. (2022). Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: Results from the open-label, randomised controlled ORAL Surveillance trial. Annals of the rheumatic diseases, 81(11), 1491-1503. https://doi.org/10.1136/ard-2022-222405

Chicago Style (17th ed.) Citation

Balanescu, Andra-Rodica, et al. "Infections in Patients with Rheumatoid Arthritis Receiving Tofacitinib Versus Tumour Necrosis Factor Inhibitors: Results from the Open-label, Randomised Controlled ORAL Surveillance Trial." Annals of the Rheumatic Diseases 81, no. 11 (2022): 1491-1503. https://doi.org/10.1136/ard-2022-222405.

MLA (9th ed.) Citation

Balanescu, Andra-Rodica, et al. "Infections in Patients with Rheumatoid Arthritis Receiving Tofacitinib Versus Tumour Necrosis Factor Inhibitors: Results from the Open-label, Randomised Controlled ORAL Surveillance Trial." Annals of the Rheumatic Diseases, vol. 81, no. 11, 2022, pp. 1491-1503, https://doi.org/10.1136/ard-2022-222405.